Quest PharmaTech Inc (QPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quest PharmaTech Inc (QPT) has a cash flow conversion efficiency ratio of -0.002x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-35.00K ≈ $-25.32K USD) by net assets (CA$23.08 Million ≈ $16.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QPT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quest PharmaTech Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Quest PharmaTech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quest PharmaTech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quest PharmaTech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
METALQUEST MINING INC.
F:E7Q
|
0.085x |
|
Traka Resources Ltd
AU:TKL
|
6.791x |
|
Gungnir Resources Inc
V:GUG
|
-0.011x |
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
-0.309x |
|
Tissue Repair Ltd
AU:TRP
|
-0.339x |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
-0.026x |
|
Pure Foods Tasmania Ltd
AU:PFT
|
-0.073x |
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
-0.171x |
Annual Cash Flow Conversion Efficiency for Quest PharmaTech Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Quest PharmaTech Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Quest PharmaTech Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | CA$21.40 Million ≈ $15.48 Million |
CA$-511.88K ≈ $-370.28K |
-0.024x | -61.77% |
| 2024-01-31 | CA$23.15 Million ≈ $16.75 Million |
CA$-342.42K ≈ $-247.70K |
-0.015x | -121.97% |
| 2023-01-31 | CA$83.25 Million ≈ $60.22 Million |
CA$-554.68K ≈ $-401.25K |
-0.007x | -252.71% |
| 2022-01-31 | CA$90.41 Million ≈ $65.40 Million |
CA$-170.78K ≈ $-123.54K |
-0.002x | +86.84% |
| 2021-01-31 | CA$175.22 Million ≈ $126.75 Million |
CA$-2.52 Million ≈ $-1.82 Million |
-0.014x | -103.71% |
| 2020-01-31 | CA$-16.50 Million ≈ $-11.93 Million |
CA$-6.38 Million ≈ $-4.61 Million |
0.387x | -75.75% |
| 2019-01-31 | CA$-4.33 Million ≈ $-3.14 Million |
CA$-6.91 Million ≈ $-5.00 Million |
1.594x | +161.66% |
| 2018-01-31 | CA$2.83 Million ≈ $2.05 Million |
CA$-7.33 Million ≈ $-5.30 Million |
-2.584x | -496.23% |
| 2017-01-31 | CA$10.63 Million ≈ $7.69 Million |
CA$-4.61 Million ≈ $-3.33 Million |
-0.433x | -141.22% |
| 2016-01-31 | CA$-2.43 Million ≈ $-1.76 Million |
CA$-2.56 Million ≈ $-1.85 Million |
1.052x | +102.15% |
| 2015-01-31 | CA$-3.73 Million ≈ $-2.70 Million |
CA$-1.94 Million ≈ $-1.41 Million |
0.520x | -35.94% |
| 2014-01-31 | CA$-2.41 Million ≈ $-1.75 Million |
CA$-1.96 Million ≈ $-1.42 Million |
0.812x | +420.61% |
| 1998-01-31 | CA$322.79K ≈ $233.50K |
CA$-81.77K ≈ $-59.15K |
-0.253x | -- |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.